Back to search results

AV-380 for Cancer Patients with Cachexia

This study is testing a drug called AV-380 in cancer patients who are experiencing cachexia, which is severe weight loss and muscle wasting. AV-380 is a type of antibody (monoclonal antibody) that aims to block a protein called GDF-15, which is thought to contribute to cachexia in cancer. The main goals are to see how safe AV-380 is, how the body processes it, and how the immune system reacts to it. You might be able to join if you are at least 18 years old, have a solid tumor cancer, are receiving standard cancer treatment, and meet specific criteria for cachexia, such as significant weight loss. The study plans to enroll 30 participants, but its current recruitment status is unclear.

Study design
This is an open-label study, meaning both you and the study team will know you are receiving AV-380. It is an ascending dose study, meaning participants will receive increasing doses of the drug. The study plans to enroll 30 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
You will be followed from enrollment to the last follow-up visit, which is approximately 60 days after your last dose.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05865535

A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia

Recruiting
PHASE1Ages 18+InterventionalTreatment
AVEO Pharmaceuticals, Inc.
~30 participants
Updated 2026-01-08 on ClinicalTrials.gov
What's tested:AV-380

At a glance

Recruiting sites
12 of 12 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Assessment of adverse events (AEs)
Measured over From enrollment to the last follow-up visit approximately 60-days post dose
+2 more outcomes measured

Conditions

Cachexia

Explore related trials

CachexiaSolid Neoplasm

NCT05865535

Where you'd take part

This study runs at 12 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Advent Health Orlando Hospital

    Orlando, Floridano site contact published

    Recruiting

  • Astera Cancer Care

    East Brunswick, New Jerseyno site contact published

    Recruiting

  • Beverly Hills Cancer Center

    Beverly Hills, Californiano site contact published

    Recruiting

  • Cancer and Blood Specialty Clinic

    Lakewood, Californiano site contact published

    Recruiting

  • Community Clinical Trials

    Kingwood, Texasno site contact published

    Recruiting

  • Hartford Hospital

    Hartford, Connecticutno site contact published

    Recruiting

  • Hoag Memorial Hospital

    Newport Beach, Californiano site contact published

    Recruiting

  • MUSC Hollings Cancer Center

    Charleston, South Carolinano site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

AVEO Clinical Trials Office
[email protected]
(857)400-0101
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Assessment of adverse events (AEs)From enrollment to the last follow-up visit approximately 60-days post dose

    AEs as characterized by incidence, type, frequency, and severity (graded according to National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE\])

  • ToxicityWhile receiving study drug (up to 4 months)

    Dose-limiting Toxicity (DLT) events observed at increasing doses of AV-380

  • Laboratory AbnormalitiesFrom enrollment to the last follow-up visit approximately 60-days post dose.

    Laboratory abnormalities as characterized by type, frequency, severity (graded according to NCI-CTCAE v5.0) and timing.